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Abstract:  Objective: To compare the efficacy of etoricoxib, lumiracoxib, celecoxib, non-selective (ns) NSAIDs and 
acetaminophen in the treatment of osteoarthritis (OA) 
Methods: Randomized placebo controlled trials investigating the effects of acetaminophen 4000mg, diclofenac 150mg, 
naproxen 1000mg, ibuprofen 2400mg, celecoxib 100-400mg, lumiracoxib 100-400mg, and etoricoxib 30-60mg with 
treatment duration of at least two weeks were identified with a systematic literature search. The endpoints of interest were 
pain, physical function and patient global assessment of disease status (PGADS). Pain and physical function reported on 
different scales (VAS or LIKERT) were translated into effect sizes (ES). An ES 0.2 - 0.5 was defined as a “small” 
treatment effect, whereas ES of 0.5 – 0.8 and > 0.8 were defined as “moderate” and “large”, respectively. A negative 
effect indicated superior effects of the treatment group compared to the control group. Results of all trials were analyzed 
simultaneously with a Bayesian mixed treatment comparison. 
Results: There is a >95% probability that etoricoxib (30 or 60mg) shows the greatest improvement in pain and physical 
function of all interventions compared. ESs of etoricoxib 30mg relative to placebo, celecoxib 200mg, ibuprofen 2400mg, 
and diclofenac 150mg were -0.66 (95% Credible Interval -0.83; -0.49), -0.32 (-0.50; -0.14), -0.25 (-0.53; 0.03), and -0.17 
(-0.41; 0.08), respectively. Regarding physical functioning, ESs of etoricoxib 30mg relative to placebo, celecoxib 200mg, 
ibuprofen 2400mg, and diclofenac 150mg were -0.61 (-0.76; -0.46), -0.27 (-0.43; -0.10), -0.20 (-0.47; 0.07), and -0.09 (-
0.33; 0.14) respectively. The greatest improvements in PGADS were expected with either etoricoxib or diclofenac. 
Conclusion: The current study estimated the efficacy of acetaminophen, nsNSAIDs, and COX-2 selective NSAIDs in OA 
and found that etoricoxib 30 mg is likely to result in the greatest improvements in pain and physical function. Differences 
in PGADS between interventions were smaller. 
Keywords: Acetaminophen, Bayesian, celecoxib, etoricoxib, lumiracoxib, NSAIDs, osteoarthritis, meta-analysis. 
INTRODUCTION 
  Osteoarthritis (OA) is the most common arthritic 
condition in adults [1]. OA is extremely painful and causes 
disability and a reduced quality of life, which poses a 
substantial economic burden for society [2-4]. 
  The principal treatment objectives in OA are to 
adequately control pain, improve function, and reduce 
disability. In order to achieve this, analgesic medication 
including acetaminophen, non-selective non-steroidal anti-
inflammatory drugs (nsNSAIDs) and more recently 
cyclooxygenase (COX) 2 selective NSAIDs are commonly 
prescribed in the treatment of OA [5]. Acetaminophen is 
used at a maximum recommended dose of 4000 mg/day and 
nsNSAIDs like naproxen at 1000 mg/day, diclofenac 150 
mg/day and ibuprofen 2400 mg/day. A Cochrane review 
demonstrated that NSAIDs display superior efficacy relative 
to acetaminophen [6]. However, concern for gastrointestinal  
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complications is a major factor limiting the use of nsNSAIDs 
at various doses [5]. The COX 2 selective class of NSAIDs 
were developed to decrease the risk of gastrointestinal tract 
injury; in OA the recommended daily doses are: celecoxib 
200mg, etoricoxib 30-60mg and lumiracoxib 100mg. (At the 
time of the writing of this manuscript (December 2007), the 
EMEA CHMP has recommended the withdrawal of the 
marketing authorisations for all lumiracoxib-containing 
medicines, because of the risk of serious side effects 
affecting the liver. [7]) 
  Medical decision making requires the assessment of the 
relative value of an intervention versus relevant comparators 
(e.g., COX 2 selective inhibitors, NSAIDs and paracetamol). 
A comprehensive relevant comparison in OA requires 
considering all available best evidence (i.e. all RCTs) of the 
above mentioned interventions. Ideally, we want a RCT that 
compares all interventions of interest simultaneously. 
However, such a study has not been performed. A mixed 
treatment comparison (MTC) is a valuable alternative to 
synthesis evidence when the interest is to compare multiple 
interventions of different RCTs [8]. MTC is an extension   
of traditional meta-analysis by including multiple different   
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pair-wise comparisons across a range of interventions [8-11]. 
With MTC the relative efficacy of a particular intervention 
versus competing interventions can be obtained in the 
absence of head-to-head comparisons; an indirect 
comparison of two interventions is made via  a common 
comparator. A Bayesian approach to a MTC can be 
considered the method of choice because it allows for a 
probabilistic interpretation and therefore leads naturally into 
the decision making context. The ranking of interventions 
regarding their ability of providing greatest outcomes 
becomes particularly useful. 
  The objective of the current study was to evaluate the 
efficacy of acetaminophen 4000mg, the nsNSAIDs 
diclofenac 150mg, naproxen 1000mg, and ibuprofen 
2400mg, and the COX-2 selective NSAIDs celecoxib and 
lumiracoxib at doses ranging from 100 to 400mg and 
etoricoxib 30mg and 60mg in the treatment of OA. 
MATERIALS AND METHODS 
Identification and Selection of Studies 
  In order to identify relevant publications a systematic 
literature review was performed. Computerised bibliographic 
databases (MEDLINE 1966 – 14
th December 2006 
November, EMBASE 1980 – 23
rd November 2006 and 
Cochrane Library issue 4 (central register of clinical trials 
and systematic reviews, until 14
th December 2006) were 
searched. The following search terms were used: celecoxib; 
Celebrex; lumiracoxib; Prexige; etoricoxib; Arcoxia; 
acetaminophen; paracetamol; diclofenac; naproxen; 
ibuprofen, randomized method; randomized trial; 
randomised method; randomised controlled trial; controlled 
trial; controlled study; controlled studies; clinical trial; 
clinical study; double blind. In addition, trials from the 
etoricoxib development program were included. The 
identified studies were included according to the following 
predetermined conditions: 
  Type of design –Randomised controlled trials with a 
double blind period. Only full-published reports were 
considered; letters and abstracts were excluded. 
 Intervention  – The interventions included acetaminophen 
4000mg/day, ibuprofen 2400mg/day, naproxen 1000mg/day, 
diclofenac 150mg/day, celecoxib 100, 200 or 400 mg/day, 
etoricoxib 30 and 60 mg/day. The duration of the 
intervention was at least 2 weeks. 
 Comparison  – Acetaminophen, a non selective NSAID or 
a COX-2 selective NSAID at mentioned dosage or placebo. 
 Study  population – All OA patients, with knee and/or hip 
as the primary affected joint. 
 Outcome  measures – In accordance with 
recommendations of OMERACT (Outcome Measures in 
Rheumatology Clinical Trials) the outcome measures 
included were: pain, physical function and patient global 
assessment [12]. The outcomes pain and physical function 
were required to be assessed by the Western Ontario and 
McMaster Universities Osteoarthritis Index  (WOMAC) 
scales. 
 Language  – Full-published reports in English were 
considered. 
Data Extraction 
  For each selected study, details were extracted on design, 
selection criteria, study population characteristics, 
interventions, outcome measures, length of follow-up, and 
results, which were subsequently checked by a second 
reviewer. With regard to etoricoxib the original company 
trial reports were available to extract outcome data. The 
outcome measures of interest were the change from baseline 
(CFB) in pain, physical functioning, and patient global 
assessment of disease status (PGADS) reported at the last 
available follow-up measurement of the double-blind 
randomized period of the RCTs. To compare VAS and likert 
scales for pain and physical function across studies and 
combine them in the MTC, CFB values were translated into 
effect sizes (ES) [13]. Relative ES were calculated as the 
difference in CFB between two interventions divided by the 
corresponding standard deviation. If the standard deviation 
was not reported, the ES was calculated by conversion of the 
reported P value to a Z-statistic according to: ES = z (1/n1 
+1/n2), where n1 and n2 are the number of patients in the 
groups that are compared. For studies that report cut-off P 
values, the quoted value (e.g., 0.05) was used to estimate the 
ES. 
Analysis 
  The results of the different regimens in the included 
studies were combined by means of a Bayesian MTC and as 
a result, estimates of relative efficacy between each of the 
possible pair-wise comparisons were obtained [8-11]. The 
interventions were acetaminophen 4000 mg/day, diclofenac 
150 mg/day, naproxen 1000 mg/day, ibuprofen 2400 
mg/day, dexibuprofen 800mg/day, celecoxib 100, 200 or 400 
mg/day, etoricoxib 30 mg/day and 60 mg/day and 
lumiracoxib 100, 200 or 400 mg/day. Analyses were 
performed for pain, physical function, and PGADS. 
  MTC within the Bayesian framework involve data, a 
likelihood distribution, a model with parameters, and prior 
distributions for these parameters. The model relates the data 
from the individual studies to basic parameters reflecting the 
(pooled) relative treatment effect of each intervention compared 
to placebo. Based on these basic parameters, the relative 
efficacy between each of the competing interventions was 
estimated. For the 3 outcomes of interest, linear models with 
normal likelihood distributions were used. A MTC relies on the 
assumption that there are no differences in the distribution of 
modifiers of the relative treatment effects across comparisons. 
For the current analyses comparability of studies was not of 
concern and as such no treatment-by-covariate interactions were 
incorporated in the models [8-11]. As with any meta-analysis, 
MTC can be performed with a fixed effects approach or a 
random effects approach. With a fixed effects model it is 
assumed that there is no heterogeneity in relative treatment 
effects across studies within comparisons. With a random 
effects model however, heterogeneity in study-specific 
treatment effects is taken into account [8-11]. For the current 
analyses random effects models were used. 
  In order to avoid that the prior beliefs influence the 
results of the model, non-informative prior distributions were 
used. Prior distributions of the relative treatment effects were 
normal distributions with mean 0 and a variance of 10,000.  
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prior distribution of heterogeneity. The posterior distribution 
can be interpreted in terms of probabilities and allows 
calculating the probability that each treatment is best out of 
those compared given the data at hand [8-11]. 
  Analyses were performed with WinBUGS 1.4 statistical 
software. Results were presented with summary statistics for the 
ES for pain and physical function and CFB treatment effects for 
PGADS: point estimate reflecting the most likely value along 
with 95% credible intervals (95% CrI) reflecting the range of 
true effects with 95% probability. Negative treatment effects 
indicate symptomatic improvement. (CrI instead of confidence 
interval are used to differentiate the uncertainty obtained with a 
Bayesian approach from that obtained with a frequentist 
approach.) In addition, the probability that a certain treatment 
out of all those compared provided greatest improvements in 
pain, physical functioning and PGADS was calculated. 
Probabilities of a ‘clinical relevant’ benefit were calculated as 
well. For this purpose an ES of  0.8 was defined as a “large” 
treatment effect. ES of 0.5 and 0.2 were defined as “moderate” 
and “small”, respectively [13]. Furthermore, in accordance with 
the Osteoarthritis Research Society International (OARSI) 
responder criteria, a relative CFB  10 mm was considered a 
clinical significant response for PGADS [14]. 
RESULTS 
Literature Search 
  With the literature search 4347 citations in OA were 
identified. After evaluation of the abstracts according to the 
predefined selection criteria, 28 citations (=30 studies) were 
identified as potential relevant and full text reports were 
obtained [15-42] in addition to 8 studies from the etoricoxib 
development program [43-48]. After evaluation of the full 
reports, 9 publications were excluded since they reported 
different outcomes [15,16], did not consider the appropriate 
doses of the treatment under study [17], were shorter than 2 
weeks [18,19], reported the outcomes of pain and physical 
function not according to the WOMAC scales or subscales 
[20,21] and did not report the results per intervention [22]. 
Since the trials from Zhao et al., [23] and Bensen et al., [24] 
were duplicate reports of one trial, only Bensen et al., [24] 
was included. Overall 29 studies (of which 28 were reported 
in 25 publications) were included in the analysis [24-48]. 
 Table  1 displays an overview of the included studies and 
interventions. Overall, the analysis included over 18,000 
patients. Double blind treatment periods ranged from 2 to 13 
weeks. The baseline characteristics of the patients in the 
different trials were comparable. The average age was about 
63 years. All patients suffered from OA for more than 3.5 
years, with an average duration of 8.7 years. Baseline scores 
of pain and physical functioning were comparable across the 
trials as well. In Tables 2-4 individual study results in terms 
of ESs and CFB are presented (along with the uncertainty 
expressed as standard errors). 
MTC Results 
Pain 
  All interventions, with the exception of acetaminophen 
and celecoxib 100 mg, were more efficacious than placebo 
(the 95% CrI of the efficacy estimates excluded zero 
difference) (Table 5a). Naproxen 1000mg, ibuprofen 
2400mg, diclofenac 150mg and celecoxib 200mg resulted in 
at least small improvements (>90% probability of ES  0.2) 
over placebo. Etoricoxib 30mg and 60mg demonstrated at 
least moderate clinical improvements over placebo (>90% 
probability of ES  0.5). There is a 96% probability that 
etoricoxib (30 or 60mg) shows the greatest improvement in 
pain of all interventions compared (Fig. 1). 
 
Fig. (1). Probability that each treatment provides the greatest 
improvements in pain, physical function and PGADS. 
  The improvements in pain with etoricoxib 30mg relative 
to other interventions ranged from ES=0.17 (diclofenac 150) 
to ES=0.57 (acetaminophen 4000) (Table 5b). Etoricoxib 
30mg is highly likely (>90% probability) to show at least 
small clinical improvements in pain over acetaminophen, 
celecoxib, and lumiracoxib. 
Physical Function 
  In terms of physical function, naproxen 1000mg, 
ibuprofen 2400mg, diclofenac 150mg, celecoxib 200mg, and 
lumiracoxib all offered at least small improvements (ES  
0.2) over placebo (Table 6a). Etoricoxib demonstrated at 
least moderate clinical improvements over placebo (>90% 
probability of ES  0.5). There is a 95% probability that 
etoricoxib showed the greatest improvement in physical 
function of all interventions compared. The ESs of 
etoricoxib relative to other interventions ranged from 0.09 
(diclofenac) to 0.57 (acetaminophen) (Table 6b). 
PGADS 
  All interventions showed improvement in PGADS over 
placebo (Table 7a). Diclofenac (-16.2), celecoxib 200 (-
14.7), etoricoxib 30 (-14.2), and etoricoxib 60 (-16.2) 
showed the greatest improvements. In Table 7b the 
differences between and etoricoxib 30 relative to other 
interventions are presented. There were no clinically relevant 
differences. 
DISCUSSION 
  The objective of the current study was to synthesize the 
evidence of acetaminophen, nsNSAIDs (naproxen, diclo-
fenac and ibuprofen) and COX-2 selective NSAIDs (etori-
coxib, celecoxib and lumiracoxib) at their recommended dose in  
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Table 1.  Overview of Study Design, Baseline Characteristics and Scales Used to Measure Pain and Physical Functioning 
 
Length  
of  
Double  
Blind  
TX  
Period 
Joints 
Randomized  
Patients  
Number 
Age 
Duration  
of  
OA  
(Years) 
Scale   Pain   Physical  
Functioning  PGADS 
 
      N tot  N  Mean  SD Mean  SD     Mean  SD Mean  SD Mean  SD 
Placebo  203 62.0 12.2 11.0 8.0  10.7  4.7 36.1 14.7         
celecoxib  100  mg  203  62.0  17.3 9.0 8.0  10.7 4.7 36.1  14.7         
celecoxib  200  mg  197 62.0 13.3 10.0 8.0  10.7  4.7 36.1 14.5         
celecoxib  400  mg  202  63.0  15.8 9.0 9.0  10.7 4.7 36.1  14.6         
Bensen  
[24] 
naproxen 1000mg  
12wk knee 1003 
198 62.0 12.2 10.0 8.0 
WOMAC  
Likert  
(pain 0-20,  
function 0-68) 
10.7  4.7  36.1  17.5       
Placebo  78  60.5  11.6        68.5  17.0  65.0  19.4        Birbara  
Study 1  
[35]  celecoxib 200 mg 
6 wks  knee  395 
157  61.3  9.2       
WOMAC  
VAS  
(0-100mm)  68.3 17.0 67.5 17.5         
Placebo  85  60.4  11.2        68.7  17.6  65.1  19.4        Birbara  
Study 2  
[35]  celecoxib 200 mg 
        
169  60.7  11.2       
WOMAC  
VAS  
(0-100mm)  66.8 17.3 63.1 19.8         
Placebo  28  61.7  9.0        198.6  110.9  697.1 375.2       
aceta.phen.4000mg  29  62.1  11.4        210.8  86.3  657.0  262.5        Case  
[36] 
diclofenac 150 mg 
12 wks  knee  82 
25  62.9  7.6       
WOMAC  
VAS 
199.8 101.5  669.3 371.6       
Placebo  231  61.5  11.7 6.6 7.0  9.9  3.3 33.0 8.5         
lumiracoxib200  mg  462  61.1  11.1 6.1 7.2  10.3 3.2 32.0 8.3         
lumiracoxib400  mg  463  60.8  11.5 6.4 7.0  9.9  3.4 33.7 8.6         
Fleischmann  
[27] 
celecoxib 200 mg 
13 wks  knee  1608 
444  61.3  11.1 6.7 8.1 
WOMAC  
Likert 
(pain 0-20,  
function 0-68) 
10.3 3.3 33.0 8.7         
acetaminph.4000 mg  94  63.1  10.9                          Geba  
[34]  celecoxib200 mg 
6 wks  knee  382 
97  62.6  11.0       
WOMAC  
VAS  
(0-100mm)                   
placebo150  mg  96 63.1 9.9  8.3 7.9  11.0 0.3 38.4 1.0         
Gibofsky  
[25]  celecoxib 200 mg 
6 wks  knee  475 
189  62.2  10.5 8.6 8.1 
WOMAC  
Likert  
(pain 0-20,  
function 0-68) 
11.2 0.3 38.8 0.8         
Placebo  218  64.0     7.9     10.5  7.2  35.3  14.7       
celecoxib 100 mg  216  65.0     7.3     10.5  7.2  33.8  14.7       
celecoxib200 mg  207  65.0     7.2     10.5  7.0  35.3  14.4       
celecoxib 400 mg  213  67.0     6.9     10.8  7.1  34.5  14.6       
Kivitz  
[31] 
naproxen 1000 mg 
12 wks  hip  1061 
207  66.0     7.3    
WOMAC  
Likert  
(pain 0-20,  
function 0-68) 
10.5  7.0  34.5  14.4       
placebo  424  61.7  10.2 3.9 5.4  9.8  3.2 35.8  10.8         
lumiracoxib 100 mg  420  62.2  10.0  4.4  5.7  9.9  3.2  35.3  11.5        Lehmann  
[39] 
celecoxib 200 mg 
13 wks  knee  1684 
420  62.9  10.5 4.4 6.2 
WOMAC  
Likert  
(pain 0-20,  
function 0-68)  10.2  3.2  36.2  10.8       
placebo  188 74.4  3.9  9.4 10.2  9.9  3.2  33.6  11.3       
celecoxib  200mg    191 75.0  4.0  10.0 8.9  10.3  3.3 35.0 10.7         
celecoxib  400mg    183 75.0  4.0  10.3 9.6  10.3  3.2 35.5 11.1         
Lisse  
[38] 
naproxen 1000 mg 
12 knee+hip  768 
206 75.0  4.1  10.4  10.7 
WOMAC  
Likert  
(pain 0-20,  
function 0-68) 
10.4  3.4  34.5  11.1       
placebo 200  60.5  34-88        10.7  3.3  37.4  11.9       
celecoxib 200 mg  201  63.0  32-85        10.6  3.1  37.4  10.4        McKenna  
[40] 
diclofenac 150 mg 
6wks knee 600 
199 63.0  29-87       
WOMAC  
Likert  
(pain 0-20,  
function 0-68)  10.7  3.1  37.5  10.4       10   The Open Rheumatology Journal, 2012, Volume 6  Stam et al. 
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Length  
of  
Double  
Blind  
TX  
Period 
Joints 
Randomized  
Patients  
Number 
Age 
Duration  
of  
OA  
(Years) 
Scale   Pain   Physical  
Functioning  PGADS 
 
      N tot  N  Mean  SD Mean  SD     Mean  SD Mean  SD Mean  SD 
placebo  374 70.0 11.0  3.8  4.0  69.0 17.0 54.0 15.0          Miceli-Richard  
[32]  acetaminph.4000 mg 
6 wks  knee  779 
405  69.0  12.0 3.8 3.8 
WOMAC 
 VAS  
(0-100mm)  66.7 18.0 54.0 15.0         
Placebo  97  61.5  9.3 8.0      9.6 3.5  32.7  10.4  62.5  18.1 
lumiracoxib 100 mg  98  61.3  8.5  7.4     9.8  3.6  31.8  12.1  63.1  17.5 
lumiracoxib 200 mg  96  59.8  9.4  6.6     9.6  3.0  31.1  11.3  62.0  18.5 
lumiracoxib 400 mg 2*dd  99  59.6  9.9  6.9     9.6  3.7  31.5  11.8  64.0  17.3 
Schnitzer  
[33] 
diclofenac 150 mg 
4 wks  knee+hip  484 
94 59.7 8.6  6.3     
WOMAC  
Likert 
(pain 0-20,  
function 0-68) 
9.5 3.4  31.1  12.6  62.2  16.2 
Placebo  382  60.8  10.5 7.0 7.4  11.0 2.9 37.2  10.5         
lumiracoxib  100  mg  391  60.2  11.1 6.9 7.7  10.8 3.1 37.3 9.8          Sheldon  
[28] 
celecoxib 200 mg 
13 wks  knee  1551 
393  60.2  10.5 6.7 7.5 
WOMAC  
Likert  
(pain 0-20,  
function 0-68)  10.8  3.2  36.9  11.0       
Placebo  150  61.8                             Smugar  
Study 1 
 [26]  celecoxib 200 mg 
6 wks  knee+hip  1521 
456  61.8          
WOMAC  
VAS 
 (0-100mm)                   
placebo 150 mg  151  62.5                             Smugar  
Study 2  
[26]  celecoxib 200 mg 
   knee+hip  1082 
460  62.0          
WOMAC  
VAS  
(0-100mm)                   
Placebo  243  64.6  9.9  4.3     10.3  3.0  34.6  10.4       
lumiracoxib 200 mg  487  64.1  10.7  4.2     10.1  3.4  34.6  11.2       
lumiracoxib 400 mg  491  64.3  10.4  5.2     10.0  3.3  33.9  11.4       
Tannenbaum  
[29] 
celecoxib 200 mg 
13 wks  knee  1702 
481 64.1 10.4  5.3     
WOMAC  
Likert  
(pain 0-20,  
function 0-68) 
10.1  3.3  34.4  11.7       
Placebo  232  62.6  11.3 8.6 8.2  10.3 3.5 34.9  12.0         
Williams  
[41]  celecoxib 200mg QD 
6 wks  knee  686 
223  62.7  10.9 8.8 7.7 
WOMAC  
Likert  
(pain 0-20,  
function 0-68) 
10.2  3.7  34.3  12.2       
Placebo  244  61.3  11.6 9.7 8.7  10.5 3.3 37.5  11.2         
Williams  
[42]  celecoxib 200mg (QD) 
6 wk  knee  718 
231  61.3  12.2 9.4 8.1 
WOMAC  
Likert 
 (pain 0-20,  
function 0-68) 
10.1  3.5  35.9  11.9       
Placebo  60  62.5  9.8  7.2  6.8  71.3     70.9     70.4    
etoricoxib 30 mg  102  61.3  10.7  8.9  7.9  67.6     65.6     66.3     p007  
[44] 
etoricoxib 60 mg 
14 wks  knee 
617 
 
112 60.0  9.6  7.6  6.9 
WOMAC  
VAS  
[0-100mm] 
66.4     63.7     64.7    
placebo  56        7.9  7.2  71.1     68.0     71.8    
etoricoxib 60 mg  222        7.1  6.9  68.9     66.4     67.6     P018 
naproxen 1000 mg 
12 wks  knee+hip 
496 
 
218        7.3  8.4 
WOMAC  
VAS  
[0-100mm] 
69.0     66.2     68.7    
placebo  56  64.1  8.9  6.3  6.4  68.7     69.0     73.6    
etoricoxib 60 mg  224  62.9  9.2  5.9  6.0  64.9     64.0     66.9    
p019  
[45] 
naproxen 1000 mg 
12 wks  knee+hip 
501 
 
221 63.2  9.3  6.3  6.5 
WOMAC  
VAS  
[0-100mm] 
65.7     63.7     67.8    
Placebo  104  59.5  8.4  6.9  6.8  69.5     70.1     72.6    
Etoricoxib 30 mg  214  63.1  10.6  7.9  8.6  68.7     68.1     72.2    
P071  
[43] 
Ibuprofen 2400 mg 
12 wks  knee+hip 
528 
 
210 61.3  9.6  8.2  7.7 
WOMAC 
VAS  
[0-100mm] 
67.8     67.8     70.5    
Placebo  111  64.0  10.1  6.5  6.6  64.7     64.2     66.9    
Etoricoxib 30 mg  224  62.1  9.0  6.6  7.3  66.5     64.3     70.1    
P073  
[47] 
Ibuprofen 2400 mg 
12 wks  knee+hip 
548 
 
213 62.3  9.6  6.7  8.1 
WOMAC  
VAS  
[0-100mm] 
64.7     62.5     69.9    Efficacy of COX-2 Selective NSAIDs, Non-Selective NSAIDs and Acetaminophen in OA  The Open Rheumatology Journal, 2012, Volume 6   11 
 
the treatment of OA. For pain and physical function both 
etoricoxib 30mg and 60mg were expected to provide the 
greatest improvements of all interventions compared. Small 
clinically relevant benefits can be expected over 
acetaminophen and the other COX-2 selective NSAIDs. For 
PGADS etoricoxib 60mg and diclofenac 150mg were 
expected to show the greatest improvements, but differences 
versus other interventions were small, let alone clinically 
relevant. Etoricoxib 30mg demonstrated improvement in 
PGADS similar to that observed with celecoxib 200mg and 
lumiracoxib 100mg. 
  There is often an interest among physicians and decision-
makers to identify the most effective treatment among a 
range of alternatives. Although RCTs provide the best 
available evidence for the relative treatment effect of a 
particular pair-wise comparison, RCTs often do not include 
all available comparator interventions of interest from a 
clinical decision making perspective. In order to obtain 
insight in the relative efficacy versus non-included 
interventions one has to rely on indirect comparisons or 
mixed treatment comparisons. MTC can be considered a 
method by which simultaneously multiple meta-analyses of 
different pair-wise comparisons across a range of different 
interventions are performed. In general, with MTC the same 
assumptions apply as with traditional meta-analysis for one 
type of comparison. Of key importance in both meta-analysis 
and MTC is not to ‘break randomization’ and only perform 
analysis with relative effects (8-11). (It is incorrect to simply 
compare the absolute PGADS improvement observed with 
etoricoxib in one trial with the absolute improvement 
observed with a comparator in another study. One reason is 
that part of the absolute reduction can be attributed to the 
efficacy of the drug, whereas another part is due to a placebo 
effect.) 
  Given the included studies in a MTC, for some 
comparisons direct (head-to-head) evidence is available, for 
some comparisons only indirect evidence, and for some 
possibly both. In the current analysis for example, the 
relative treatment effect of etoricoxib versus lumiracoxib 
was obtained through indirect comparisons only. Leung et 
al., [45] directly compared etoricoxib 60 mg and naproxen 
1000 mg, whereas Gottesdiener et al., [44] in combination 
with Bensen [24], Kivitz [31], and Lisse [38] provided 
indirect evidence for this comparison through a common 
placebo arm. It is important that the indirect comparisons are 
not biased; the indirect comparisons should estimate the 
same ‘true’ underlying treatment effect as the direct 
comparisons, otherwise we combine unbiased direct 
estimates of a treatment effect with biased inidirect estimates 
of that treatment effect resulting in biased mixed estimates. 
Although only RCTs are included in the MTC, it is 
important to realize that the value of randomization does not 
hold across trials. As a result there is the risk that patients 
assigned to the different trials are not comparable regarding 
certain characteristics. If these patient characteristics or 
baseline risk differences across trials are associated with 
differences in the treatment effect (i.e. treatment effect 
modifiers) there can be across study heterogeneity within 
direct comparisons, biased indirect or mixed comparisons, or 
both. Differences in study characteristics can also be a 
source of heterogeneity or bias. To capture heterogeneity a 
random effects model was used. If there is a bias in the 
indirect and mixed estimates due to systematic differences in 
observed effect modifiers across comparisons, this can be 
explained by means of meta-regression models [11]. 
(Table 1) contd….. 
Length  
of  
Double  
Blind  
TX  
Period 
Joints 
Randomized  
Patients  
Number 
Age 
Duration  
of  
OA  
(Years) 
Scale   Pain   Physical  
Functioning  PGADS 
 
      N tot  N  Mean  SD Mean  SD     Mean  SD Mean  SD Mean  SD 
Placebo  127  62.8  9.7  9.0  8.7  66.6     64.7     69.1    
Etoricoxib 30mg  231  62.1  10.2  8.6  8.9  67.4     65.5     72.2    
P076  
[48] 
Celecoxib 200mg 
12 wks  knee+hip 
599 
 
241 62.5  9.3  8.4  8.7 
WOMAC  
VAS  
[0-100mm] 
67.5     66.6     71.3    
Placebo  117  60.9  8.6  7.2  6.6  66.4     65.2     72.3    
Etoricoxib 30mg  243  61.9  9.6  7.8  8.3  68.7     67.7     73.0     P077  
[48] 
Celecoxib 200mg 
12 wks  knee+hip 
608 
 
247 62.2  9.5  8.3  8.7 
WOMAC  
VAS 
 [0-100mm] 
67.3     65.8     70.1    
acetaminph. 4000 mg  269  61.9  10.7                          Schnitzer  
[37]  celecoxib 200 mg 
6 wks  knee  1578 
523  61.4  9.9       
WOMAC  
VAS 
 [0-100mm]                    
dexibuprofen800 mg   74  55.3  10.1        10.5  2.3  36.9  7.8       
Hawel  
[30]  celecoxib200mg  
15 days  hip 148 
74  53.2  9.4       
WOMAC 
LIKERT 
 [pain 0-20,  
function 0-68] 
10.4 2.4 36.8 9.6         
etoricoxib 60 mg  256  63.1  9.7  7.5  6.8  62.8  17.0   62.7   18.2   70.7   17.2  805-01 
[46]  Diclofenac-sodium 150 mg 
6 wks  knee+hip 
516 
  260 63.0  9.8  7.5  6.6 
WOMAC VAS  
[0-100mm]  62.0  17.5   59.9   18.5   69.0   17.1 12   The Open Rheumatology Journal, 2012, Volume 6  Stam et al. 
   
Table 2.  Overview of the Treatment Effects (Effect Sizes) Versus Placebo or Active Intervention by Study for Pain 
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0
 
 
  ES*  se  ES  se  ES  se    ES  se  ES  se  ES  se  ES  se  ES  Se  ES  se  ES  se  ES  se  ES  Se 
Bensen  
[24]  Ref      -0.16  0.1            -0.14  0.1  -0.34  0.1  -0.27 0.1                     
Birbara  
Study 1  
[35] 
Ref                        -0.16  0.14                         
Birbara  
Study 2  
[35] 
Ref                        -0.19  0.13                         
Case 
 [36]  Ref  -0.09  0.27            -0.43 0.28                                 
Fleischmann  
[27]  Ref                        -0.3  0.08      -0.34 0.08      -0.34 0.08         
Geba  
[34]***    0.16  0.15                    Ref                           
Gibofsky  
[25]  Ref                        -0.52  0.13                         
Kivitz  
[31]  Ref      -0.2  0.1            -0.08  0.1  -0.14  0.1  -0.17 0.1                     
Lehmann  
[39]  Ref                        -0.23  0.07      -0.22 0.07                 
Lisse 
 [38]  Ref      -0.31  0.1                -0.32  0.1  -0.32 0.1                     
McKenna  
[40]  Ref                -0.45  0.1      -0.39  0.1                         
Miceli- 
Richard 
 [32] 
Ref  0.00  0.07                                               
Schnitzer  
[33]  Ref                -0.4  0.15              -0.42 0.15  -0.3  0.15  -0.37 0.15         
Sheldon 
 [28]  Ref                        -0.27  0.07      -0.32 0.07                 
Smugar  
study 1  
[26] 
Ref                        -0.51  0.09                         
Smugar  
study 2  
[26] 
Ref                        -0.65  0.1                         
Tannenbaum 
[29]  Ref                        -0.18  0.08          -0.19  0.08  -0.21 0.08         
Williams  
[41]  Ref                        -0.32  0.09                         
Williams 
 [42]  Ref                        -0.29  0.09                         
P007 
 [44]  Ref                                            -0.67  0.17  -1.08 0.17 
P018  
[np]  Ref      -0.79 0.15                                        -0.66 0.15 Efficacy of COX-2 Selective NSAIDs, Non-Selective NSAIDs and Acetaminophen in OA  The Open Rheumatology Journal, 2012, Volume 6   13 
 
  In the current analysis, the included studies were similar 
with regard to patient characteristics which exclude these 
factors causing bias in the indirect and mixed estimates [10-
11]. Accordingly, no meta-regression models were used [11]. 
However, we have to keep in mind that there is small chance 
that unknown or unmeasured patient characteristics are 
different across trials and might cause bias. 
  Some of the included studies did not explicitly apply the 
‘flare’ criterion for inclusion of patients [30,32,35,39]. The 
flare criterion relates to the fact that following 
discontinuation (“washout”) of previously used NSAIDs 
patients demonstrate sufficient disease activity. These trials 
might have included patients that were less responsive to 
treatment. Sensitivty analyses excluding these trials provided 
similar results as the reported findings in this report. Hence, 
the ‘flare’ criterion seems not a source for bias. 
  The included studies had treatment durations varying 
from 2 to 13 weeks. It is known that maximum or near 
maximum efficacy of NSAIDs is achieved by week 2 and 
maintained throughout week 12 [44,45]. Hence, these 
differences in study design cannot be a source of bias. 
However Lee et al., suggested that trials studying COX-2 
selective NSAIDs that were initiated by different sponsors 
might be different regarding assay sensitivity [49]. This 
might be an issue for the indirect comparison of etoricoxib 
versus lumiracoxib. 
 
 
  We consider the performed analysis relevant for clinical 
decision-making, for several reasons. First, evidence of 
efficacy is obtained for the all relevant interventions by 
means of a systematic review of RCTs and the synthesis of 
evidence is based on current state-of the-art methods. 
Second, the endpoints considered encompass the full core set 
of outcomes recommended by OMERACT a world-wide 
consensus group of experts [12] and the analysis allowed for 
interpreting the estimated effect sizes regarding their clinical 
relevance. For pain and physical function effect sizes of 0.2 -
0.5, 0.5 -0.8 and >0.8 indicated ‘small’, ‘moderate’ and 
‘large’ improvements, respectively [13]. For PGADS a 
treatment difference of at least 10 mm VAS was assumed to 
represent a clinical relevant difference [14]. Third, the 
Bayesian approach of the MTC allowed for probabilistic 
interpretation of the findings. The estimated size of the 
treatment effect as well as the associated uncertainty of each 
intervention was translated into one measure: The 
probability that a certain treatment out of all treatments 
compared provided greatest outcomes. This measure leads 
into a decision-making context. For example, with regard to 
pain etoricoxib (30 or 60mg) was associated with a 96% 
probability of providing the greatest improvements. (This 
corresponds to a probability of 4% of making the wrong 
decision when etoricoxib is identified as the treatment that 
results in the greatest improvement in pain.) 
 
 
 
(Table 2) contd….. 
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  ES*  se  ES  se  ES  se    ES  se  ES  se  ES  se  ES  se  ES  Se  ES  se  ES  se  ES  se  ES  Se 
P019  
[45] 
Ref      -0.5  0.15                                        -0.52 0.15 
P071  
[43] 
Ref          -0.43  0.12                                -0.51 0.12     
P073  
[47] 
Ref          -0.38  0.12                                -0.58 0.12     
P076  
[48] 
Ref                        -0.56 0.11                  -0.7  0.11     
P077  
[48] 
Ref                        -0.55 0.12                  -0.69 0.12     
Schnitzer  
2005 ***  
[37] 
  0.21  0.08                    Ref                           
Hawel  
[30] **** 
              Ref          0.05  0.18                         
805-01***** 
[46] 
                Ref                                -0.02 0.09 
*ES=Effect size. small (ES  0.2), moderate (ES  0.5) or large ((ES  0.8). negative effect sizes indicate improvement; ** se = standard error of the effect size 
***Versus celecoxib 200, **** versus dexibuprofen 800, *****versus diclofenac 150. 14   The Open Rheumatology Journal, 2012, Volume 6  Stam et al. 
   
Table 3.  Overview of the Treatment Effects (Effect Sizes) Versus Placebo or Active Intervention by Study for Physical Function 
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    ES se ES se ES se    ES se ES  se  ES se ES  se  ES se ES se ES se ES se ES se 
Bensen 
[24] 
Ref     -0.14  0.1        - 0 . 1   0.1 -0.29  0.1  -0.2  0.1            
Birbara 
Study 1 
[35] 
Ref 
             -0.15 0.14                
Birbara 
Study 2 
[35] 
Ref 
              - 0 . 1 5  0.13                
Case 
[36] 
Ref  0.2  0.27        - 0 . 3 6  0.28                      
Fleischmann 
[27] 
Ref                - 0 . 3 9  0.08        - 0 . 4 9  0.08 -0.46 0.08      
Geba 
[34]*** 
  0.24 0.15             R e f                  
Gibofsky 
[25] 
Ref                - 0 . 4 8  0.13                
Kivitz 
[31] 
Ref     -0.31  0.1        - 0 . 1 9  0.1 -0.24  0.1  -0.25 0.1            
Lehmann 
[39] 
Ref                     - 0 . 1 9  0.07 -0.18 0.07        
Lisse 
[38] 
Ref     -0.31  0.1           - 0 . 3 2   0.1  -0.32 0.1            
McKenna 
[40] 
Ref          - 0 . 5 3   0.1     -0.4  0.1                
Miceli-Richard 
[32] 
Ref  0.00 0.07                             
Schnitzer 
[33] 
Ref          - 0 . 3 8  0.15           - 0 . 3 2  0.15 -0.17 0.15 -0.35 0.15      
Sheldon 
[28] 
Ref                - 0 . 3 6  0.07     -0.45 0.07          
Smugar 
study 1 
[26] 
Ref 
              - 0 . 5 1  0.09                
Smugar 
study 2 
[26] 
Ref 
              - 0 . 6 4   0.1                
Tannenbaum 
[29] 
Ref                - 0 . 2 6  0.08        - 0 . 3   0.08 -0.28 0.08      
Williams 
[41] 
Ref                - 0 . 2 6  0.09                
Williams 
[42] 
Ref                - 0 . 2   0.09                
P007 
[44] 
Ref                            - 0 . 5 9  0.17 -0.96 0.17 
P018 
[np] 
Ref     -0.89 0.16                          - 0 . 7 9  0.15 Efficacy of COX-2 Selective NSAIDs, Non-Selective NSAIDs and Acetaminophen in OA  The Open Rheumatology Journal, 2012, Volume 6   15 
   
(Table 3) contd….. 
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    ES se ES se ES se    ES se ES  se  ES se ES  se  ES se ES se ES se ES se ES se 
P019 [45]  Ref      -0.42 0.15                          - 0 . 4 2  0.15 
P071 [43]  Ref          -0.46 0.12                      - 0 . 5   0 . 1 2     
P073 [47]  Ref          -0.36 0.12                      - 0 . 5 1  0.12    
P076  [48]  Ref               -0.57 0.11             - 0 . 7 2  0.11    
P077  [48]  Ref               -0.61 0.12             - 0 . 7 1  0.12    
Schnitzer 
2005*** 
[37] 
 
0.24 0.08             R e f                  
Hawel 
[30]**** 
         Ref        0.01  0.18                
805-01***** 
[46] 
          R e f                       - 0 . 0 2  0.09 
* ES=Effect size. small (ES  0.2), moderate (ES  0.5) or large ((ES  0.8). negative effect sizes indicate improvement; ** se = standard error of the effect size. 
***versus celecoxib 200, **** versus dexibuprofen 800, *****versus diclofenac 150. 
 
Table 4.  Overview of the Treatment Effects Versus Placebo or Active Intervention by Study for PGADS Expressed as Difference 
in Change from Baseline 
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Schnitzer  
[33]  Ref       -15.3  3.65       -11.8  3.59  -11.7  3.67  -14  3.74      
Smugar  
study 1  
[26] 
Ref         -14.5  2.21                
Smugar  
study 2  
[26] 
Ref           -16.1  2.21             
P007  [44]  Ref                     -16.3  3.57  -25.3  3.54 
P018  [np]  Ref  -18.6  3.29                     -16.6  3.29 
P019  [45]  Ref  -7.6  3.16                     -9.3  3.16 
P071  [43]  Ref     -11.4  2.66                    
P073  [47]  Ref     -8.1  2.65                 -11.7  2.63    
P076  [48]  Ref           -12.4  2.47           -16.4  2.48    
P077  [48]  Ref           -15.9  2.55           -15.9  2.56    
805-01***  [46]            Ref              0.2  1.51 
*Difference in change from baseline of intervention group versus placebo (or versus celecoxib in study 805-01). Negative effect indicates improvement favoring the active 
intervention reported in the table. 
***versus celecoxib 200. 16   The Open Rheumatology Journal, 2012, Volume 6  Stam et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5a.  Pain: Treatment Effects Relative to Placebo 
 
    95% CrI  Probability that Treatment Shows Small, Moderate or Large Improvement Relative to Placebo* 
Treatment (mg)  ES**  Low  High  Small Moderate Large 
acetaminophen 4000  -0.09  -0.25  0.08  0.08  0.00  0 
nsNSAIDs           
naproxen 1000  -0.39  -0.53  -0.26  >0.99  0.06  0.00 
ibuprofen 2400  -0.41  -0.63  -0.18  0.96  0.20  0.00 
diclofenac 150  -0.49  -0.67  -0.31  >0.99  0.47  0.00 
COX-2 selective NSAIDs           
celecoxib 100  -0.11  -0.31  0.10  0.18  0.00  0.00 
celecoxib 200   -0.34  -0.41  -0.27  >0.99  0.00  0.00 
celecoxib 400  -0.27  -0.45  -0.10  0.81  0.01  0.00 
lumiracoxib 100  -0.30  -0.46  -0.14  0.89  0.01  0.00 
lumiracoxib 200  -0.27  -0.44  -0.10  0.80  0.00  0.00 
lumiracoxib 400  -0.29  -0.46  -0.13  0.87  0.01  0.00 
etoricoxib 30  -0.66  -0.83  -0.49  >0.99  0.97  0.05 
etoricoxib 60  -0.62  -0.78  -0.45  >0.99  0.92  0.02 
*Small (ES  0.2), moderate (ES  0.5) or large (ES  0.8). 
**Negative effect sizes indicate improvement. 
 
Table 5b.  Pain: Treatment Effects of Etoricoxib (30 mg) Relative to Comparators 
 
   95%  CrI  Probability that Etoricoxib 30 mg Shows Small, Moderate or Large Improvement Relative to  
Comparator* 
Comparator (mg)  ES**  Low  High  Small Moderate Large 
acetaminophen 4000  -0.57  -0.80  -0.34  1.00  0.73  0.03 
nsNSAIDs           
naproxen 1000  -0.27  -0.48  -0.05  0.73  0.02  0.00 
ibuprofen 2400  -0.25  -0.53  0.03  0.65  0.04  0.00 
diclofenac 150  -0.17  -0.41  0.08  0.39  0.00  0.00 
COX-2 selective NSAIDs           
celecoxib 100  -0.55  -0.81  -0.29  0.99  0.65  0.03 
celecoxib 200   -0.32  -0.50  -0.14  0.91  0.02  0.00 
celecoxib 400  -0.39  -0.62  -0.15  0.94  0.17  0.00 
lumiracoxib 100  -0.36  -0.59  -0.12  0.91  0.11  0.00 
lumiracoxib 200  -0.39  -0.62  -0.15  0.94  0.17  0.00 
lumiracoxib 400  -0.36  -0.60  -0.13  0.92  0.13  0.00 
            
*Small (ES  0.2), moderate (ES  0.5) or large (ES  0.8). 
**Negative effect sizes indicate improvement. Efficacy of COX-2 Selective NSAIDs, Non-Selective NSAIDs and Acetaminophen in OA  The Open Rheumatology Journal, 2012, Volume 6   17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6a.  Physical Function: Treatment Effects Relative to Placebo 
 
      95% CrI  Probability that Treatment Shows Small, Moderate or Large Improvement Relative to Placebo* 
Treatment (mg)  ES**  Low  High  Small Moderate Large 
acetaminophen 4000  -0.04  -0.20  0.13  0.03  0  0 
nsNSAIDs           
naproxen 1000  -0.37  -0.51  -0.23  0.99  0.04  0.00 
ibuprofen 2400  -0.41  -0.64  -0.18  0.96  0.22  0.00 
diclofenac  150 -0.52  -0.70  -0.33 >0.99  0.58  0.00 
COX-2 selective NSAIDs           
celecoxib 100  -0.15  -0.35  0.06  0.30  0.00  0.00 
celecoxib 200   -0.34  -0.42  -0.27  >0.99  0.00  0.00 
celecoxib 400  -0.26  -0.43  -0.09  0.74  0.00  0.00 
lumiracoxib 100  -0.32  -0.48  -0.15  0.92  0.02  0.00 
lumiracoxib 200  -0.35  -0.52  -0.17  0.95  0.04  0.00 
lumiracoxib 400  -0.36  -0.53  -0.20  0.97  0.05  0.00 
etoricoxib 30  -0.61  -0.76  -0.46  >0.99  0.93  0.01 
etoricoxib 60  -0.64  -0.83  -0.46  >0.99  0.93  0.05 
*Small (ES  0.2), moderate (ES  0.5) or large (ES  0.8). 
**Negative effect sizes indicate improvement. 
 
Table 6b.  Physical Function: Treatment Effects of Etoricoxib 30 mg Relative to Comparators 
 
      95% CrI  Probability that Etoricoxib 30 mg Shows Small, Moderate or Large Improvement Relative to 
Comparator* 
Comparator (mg)  ES**  Low  High  Small  Moderate  Large 
acetaminophen 4000  -0.57  -0.79  -0.35  1.00  0.74  0.02 
nsNSAIDs           
naproxen 1000  -0.24  -0.45  -0.04  0.66  0.01  0.00 
ibuprofen 2400  -0.20  -0.47  0.07  0.50  0.02  0.00 
diclofenac 150  -0.09  -0.33  0.14  0.18  0.00  0.00 
COX-2 selective NSAIDs           
celecoxib 100  -0.46  -0.72  -0.21  0.98  0.39  0.01 
celecoxib 200   -0.27  -0.43  -0.10  0.79  0.00  0.00 
celecoxib 400  -0.35  -0.58  -0.13  0.91  0.10  0.00 
lumiracoxib 100  -0.29  -0.52  -0.07  0.80  0.03  0.00 
lumiracoxib 200  -0.26  -0.49  -0.04  0.71  0.02  0.00 
lumiracoxib 400  -0.25  -0.47  -0.02  0.66  0.01  0.00 
*Small (ES  0.2), moderate (ES  0.5) or large (ES  0.8). 
**Negative effect sizes indicate improvement. 18   The Open Rheumatology Journal, 2012, Volume 6  Stam et al. 
CONCLUSION 
  The current study estimated the treatment effects of 
acetaminophen nsNSAIDs and COX-2 selective NSAIDs in 
OA and indicated that etoricoxib is likely to result in the 
greatest improvements in pain and physical function. 
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